Cochlear ImplantsNCT03078920
Benefits of a Contralateral Routing of Signals (CROS) System in Unilateral CI-recipients
A study testing Naída CROS in people with Cochlear Implants, run by Advanced Bionics AG at 1 site in France.
Trial summary
The objective is to investigate the new Naida CROS device in adult recipients including chronic phases and to generate some preliminary pre-launch data. The formal study objectives are to compare the speech intelligibility in quiet and noise when using the CROS device with the Naida CI Q70 processor versus the Naida… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cochlear Implants
- What is being tested?
- Naída CROS
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 13 participants
- Where
- 1 siteFrance
- Study dates
- 23 Mar 2017to 19 Jul 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age of 18 years or older
- Unilaterally implanted with an Advanced Bionics Clarion or HiRes90k (implant type) implant
- At least 6 months of cochlear implant use
- At least 3 months experience with the Naída CI processor
- No benefit or limited benefit with a contralateral hearing aid
- Minimum speech understanding level in quiet of 30% (Lafon lists)
Show all 9Show fewer
- Ability to wear the Naída CROS device on their contralateral ear and to have sufficient dexterity and understanding to handle both the Naída CI and CROS devices
- Able to describe the sound quality that they receive
- French language proficiency
Who cannot join
- Persons mentioned in the following articles of the French public health code: articles from L. 1121-5 to L.1121-8
- Participating in another clinical study
- Difficulties additional to hearing impairment that would interfere with the study procedures
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Subjective and Objective Benefits of a Contralateral Routing of Signals (CROS) System in Unilateral Cochlear Implant Recipients
The objective is to investigate the new Naida CROS device in adult recipients including chronic phases and to generate some preliminary pre-launch data.
The formal study objectives are to compare the speech intelligibility in quiet and noise when using the CROS device with the Naida CI Q70 processor versus the Naida CI processor alone in quiet and noise conditions. Subjects will be tested with and without CROS at the baseline visit and then at follow-up visits taking place one month and three months after baseline. Subjects will use the new device at home between the first two visits appointments and then will only use the Naida CI processor for two additional weeks to better evaluate the handicap of not having access to contralateral signal input. There will be four visits to the centre in total.
Read more
Subjective feedback will be collected through questionnaire like the APHAB and Speech, Spatial and Qualities of Hearing Scale (SSQ). A customised questionnaire focusing usability and benefit of the CROS will also be administered.
Additional interest of the study will be to evaluate any acclimatisation effect with the CROS device both objectively and subjectively.
Read the detailed description
Nowadays, cochlear implants (CI) are widely used prostheses for deaf people. They are stimulating the auditory nerve cells electrically, circumventing the tympanic membrane and ossicles of the middle ear and the inner and outer hair cells of the inner ear. A single cochlear implant usually provides substantial benefit to recipients who were previously severe-to-profoundly deaf. In quiet listening situations, scores for the perception of sentences typically show a strong ceiling effect . However, in even moderately challenging listening situations, where speech needs to be understood when presented at lower levels or in the presence of competing noise, speech perception scores drop to below the level required to support practical communication. The speech reception threshold (SRT), the signal-to-noise ratio (SNR) required to understand 50% of words in sentences for normal hearing subjects listening in their first language, is around -6 decibel (dB). For CI recipients this can be +9 to +15 dB. These figures relate to a test situation where target speech comes from directly in front of the CI recipient. If sound comes from their un-implanted side, it will typically suffer a further 6 dB of attenuation, a figure in agreement with published literature, with the information rich higher frequencies being even more attenuated. This puts unilaterally implanted CI users in a very difficult position. Bilateral cochlear implantation has been shown to provide advantages although its main advantage is in dealing with the head shadow problem, rather than restoring true binaural hearing advantages such as spatial release from masking. Bilateral implantation is obviously expensive and not available to adults in many countries. In addition, some subjects cannot get a second implant due to medical reasons or they do not want to undergo a second surgery. These subjects will have similar limitations as single-sided deaf (SSD) patients: due to the head shadow effect, soft sounds from the direction of the non-implanted side will not be heard. To overcome these limitations, the contralateral routing of signals (CROS) by means of a contralateral receiver could be a very beneficial tool. This system has already been used in the hearing instrument field for a while and showed benefit to patients suffering from single-sided deafness. Some preliminary studies using experimental devices were also conducted with cochlear implants users showing similar benefits.
A comparable system, the Naída CROS device, developed by Advanced Bionics as contralateral receiver will be evaluated in this study. The Naída CROS device is placed on the contralateral ear similar to a small hearing aid. It captures the incoming sound and transmits it wirelessly to the CI sound processor. In the sound processor, signals from both the ipsilateral and the contralateral side are mixed together.
While some work has been done acutely with hearing instrument prototypes, this study will evaluate the Naída CI device with the Naída CROS device and involve take home experience. The study will evaluate the benefit of adding a CROS device to unilaterally implanted subjects both objectively and subjectively.
A microphone is placed at the unilateral CI recipient's non-implanted ear. This microphone can then detect sounds from the head-shadowed side and route them to the CI sound processor. In the hearing instrument field such systems have been commonly applied for cases of unilateral deafness and are referred to as contralateral routing of signal or CROS systems. The most recent Advanced Bionics sound processors, the Naída CI Q70 and Q90, have the ability to communicate wirelessly with another Naída CI processor, or with some Phonak hearing instrument models, including a CROS device, placed on the contralateral ear. The full microphone signal is transmitted wirelessly to the Naída CI sound processor and can be mixed with the microphone signal from the implanted side. The Naída CROS device is based on the Phonak CROS H20 device hardware. It contains essentially a microphone, radio transmitter and battery so it is small and discrete. The Naída CROS device is designed to be an out-of-the-box solution to work automatically with the Naída CI without the need for fitting.
The Naída CI processors will be programmed using the conventional fitting software SoundWave (version 3.1) provided by Advanced Bionics, to enable wireless communication between the CI and Naída CROS devices. The software is not yet CE approved, but is tested with respect to the company's internal standards. The CE approved CI system as a whole is still used in its intended way during the study, i.e. to "restore a level of auditory sensation". All basic safety features incorporated in the implant system remain active and are not affected by the study. The Naída CROS device also works in its intended way without the need for programming. However, the investigational Naída CROS device will be pre-configured with a research software to instantaneously communicate with the approved Naída CI processor when switched on.
- Conditions
- Cochlear Implants
- Being tested
- Naída CROS
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Naída CROSDevice
At fitting Naída CROS and a loaner Naída CI processor are used for the duration of the study. The fitting software allows to enable a HIBAN link between the CI processor and the Naída CROS. The fitting of the CI processor is based on the clinical programming of the subject. No changes are made to the fitting parameters unless the subject requests changes. The fitting is done according to the clinical routine. The Naída CROS is pre-configured to communicate with the Naída CI when switched on.
| Study group | Role | What they receive |
|---|---|---|
| 11 unilateral adult cochlear implant users | Other | Speech Reception Threshold (SRT) measured with an adaptive test Receives: Device: Naída CROS |
What is being measured
The primary outcome is the main question the study is designed to answer.
Speech Reception Threshold (SRT) measured with an adaptive test (French Matrix sentence test)
Speech tests in quiet \& noise with the Naída CI processor alone and with the Naída CROS device
Measured: Baseline
Speech Reception Threshold (SRT) measured with an adaptive test (French Matrix sentence test)
Speech tests in quiet \& noise with the Naída CI processor alone and with the Naída CROS device
Measured: 1 month
Speech Reception Threshold (SRT) measured with an adaptive test (French Matrix sentence test)
Speech tests in quiet \& noise with the Naída CI processor alone and with the Naída CROS device
Measured: 3 months
Speech Reception Threshold (SRT) measured with an adaptive test (French Matrix sentence test)
Questionnaires about Naída CI sound processor and Naída CROS device listening condition
Measured: Baseline
Speech Reception Threshold (SRT) measured with an adaptive test (French Matrix sentence test)
Questionnaires about Naída CI sound processor and Naída CROS device listening condition
Measured: 1 month
Speech Reception Threshold (SRT) measured with an adaptive test (French Matrix sentence test)
Questionnaires about Naída CI sound processor and Naída CROS device listening condition
Measured: 3 months
Secondary outcomes (8)
Questionnaires about Naída CI sound processor listening condition
Evaluate the benefit/usability of the Naída CROS device in everyday life
Measured: Baseline
Questionnaires about Naída CI sound processor listening condition
Evaluate any acclimatization effect of using the Naída CROS device
Measured: Baseline
Questionnaires about Naída CI sound processor listening condition
Evaluate the benefit/usability of the Naída CROS device in everyday life
- Evaluate any acclimatization effect of using the Naída CROS device
Measured: 1 months
Questionnaires about Naída CI sound processor listening condition
Evaluate any acclimatization effect of using the Naída CROS device
Measured: 1 months
Questionnaires about Naída CI sound processor listening condition
Evaluate the benefit/usability of the Naída CROS device in everyday life
Measured: 3 months
Questionnaires about Naída CI sound processor listening condition
Evaluate any acclimatization effect of using the Naída CROS device
Measured: 3 months
Questionnaires about Naída CI sound processor listening condition
Evaluate the benefit/usability of the Naída CROS device in everyday life
Measured: 3.5 months
Questionnaires about Naída CI sound processor listening condition
Evaluate any acclimatization effect of using the Naída CROS device
Measured: 3.5 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Mar 2017
- Study start23 Mar 2017
- Primary completion19 Jul 2017
- Study completion19 Jul 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cochlear ImplantsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Device feasibility
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 13 participants (actual)
Sponsor and investigators
- Lead sponsor
- Advanced Bionics AG
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Volkmar Hamacher, Dr., Study chair, Advanced Bionics GmbHIsabelle MOSNIER, Dr., Principal investigator, Groupe Hospitalier de la PITIE-SALPETRIERE
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03078920
- Sponsor's protocol ID
- ABIntl-16-04
- Status last verified
- Aug 2017
- First submitted
- 21 Feb 2017
- Last updated
- 11 Aug 2017
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Aug 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Subjective and Objective Benefits of a Contralateral Routing of Signals (CROS) System in Unilateral Cochlear Implant Recipients
- ClinicalTrials.gov ID
- NCT03078920
- Acronym / sponsor ID
- ABIntl-16-04
- Conditions
- Cochlear Implants
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 13 participants (actual)
- Lead sponsor
- Advanced Bionics AGIndustry (pharma, biotech, devices)
- Study start
- 23 Mar 2017 (actual)
- Primary completion
- 19 Jul 2017 (actual)
- Study completion
- 19 Jul 2017 (actual)
- First posted
- 14 Mar 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective is to investigate the new Naida CROS device in adult recipients including chronic phases and to generate some preliminary pre-launch data.
The formal study objectives are to compare the speech intelligibility in quiet and noise when using the CROS device with the Naida CI Q70 processor versus the Naida CI processor alone in quiet and noise conditions. Subjects will be tested with and without CROS at the baseline visit and then at follow-up visits taking place one month and three months after baseline. Subjects will use the new device at home between the first two visits appointments and then will only use the Naida CI processor for two additional weeks to better evaluate the handicap of not having access to contralateral signal input. There will be four visits to the centre in total.
Subjective feedback will be collected through questionnaire like the APHAB and Speech, Spatial and Qualities of Hearing Scale (SSQ). A customised questionnaire focusing usability and benefit of the CROS will also be administered.
Additional interest of the study will be to evaluate any acclimatisation effect with the CROS device both objectively and subjectively.
Detailed description
Nowadays, cochlear implants (CI) are widely used prostheses for deaf people. They are stimulating the auditory nerve cells electrically, circumventing the tympanic membrane and ossicles of the middle ear and the inner and outer hair cells of the inner ear. A single cochlear implant usually provides substantial benefit to recipients who were previously severe-to-profoundly deaf. In quiet listening situations, scores for the perception of sentences typically show a strong ceiling effect . However, in even moderately challenging listening situations, where speech needs to be understood when presented at lower levels or in the presence of competing noise, speech perception scores drop to below the level required to support practical communication. The speech reception threshold (SRT), the signal-to-noise ratio (SNR) required to understand 50% of words in sentences for normal hearing subjects listening in their first language, is around -6 decibel (dB). For CI recipients this can be +9 to +15 dB. These figures relate to a test situation where target speech comes from directly in front of the CI recipient. If sound comes from their un-implanted side, it will typically suffer a further 6 dB of attenuation, a figure in agreement with published literature, with the information rich higher frequencies being even more attenuated. This puts unilaterally implanted CI users in a very difficult position. Bilateral cochlear implantation has been shown to provide advantages although its main advantage is in dealing with the head shadow problem, rather than restoring true binaural hearing advantages such as spatial release from masking. Bilateral implantation is obviously expensive and not available to adults in many countries. In addition, some subjects cannot get a second implant due to medical reasons or they do not want to undergo a second surgery. These subjects will have similar limitations as single-sided deaf (SSD) patients: due to the head shadow effect, soft sounds from the direction of the non-implanted side will not be heard. To overcome these limitations, the contralateral routing of signals (CROS) by means of a contralateral receiver could be a very beneficial tool. This system has already been used in the hearing instrument field for a while and showed benefit to patients suffering from single-sided deafness. Some preliminary studies using experimental devices were also conducted with cochlear implants users showing similar benefits.
A comparable system, the Naída CROS device, developed by Advanced Bionics as contralateral receiver will be evaluated in this study. The Naída CROS device is placed on the contralateral ear similar to a small hearing aid. It captures the incoming sound and transmits it wirelessly to the CI sound processor. In the sound processor, signals from both the ipsilateral and the contralateral side are mixed together.
While some work has been done acutely with hearing instrument prototypes, this study will evaluate the Naída CI device with the Naída CROS device and involve take home experience. The study will evaluate the benefit of adding a CROS device to unilaterally implanted subjects both objectively and subjectively.
A microphone is placed at the unilateral CI recipient's non-implanted ear. This microphone can then detect sounds from the head-shadowed side and route them to the CI sound processor. In the hearing instrument field such systems have been commonly applied for cases of unilateral deafness and are referred to as contralateral routing of signal or CROS systems. The most recent Advanced Bionics sound processors, the Naída CI Q70 and Q90, have the ability to communicate wirelessly with another Naída CI processor, or with some Phonak hearing instrument models, including a CROS device, placed on the contralateral ear. The full microphone signal is transmitted wirelessly to the Naída CI sound processor and can be mixed with the microphone signal from the implanted side. The Naída CROS device is based on the Phonak CROS H20 device hardware. It contains essentially a microphone, radio transmitter and battery so it is small and discrete. The Naída CROS device is designed to be an out-of-the-box solution to work automatically with the Naída CI without the need for fitting.
The Naída CI processors will be programmed using the conventional fitting software SoundWave (version 3.1) provided by Advanced Bionics, to enable wireless communication between the CI and Naída CROS devices. The software is not yet CE approved, but is tested with respect to the company's internal standards. The CE approved CI system as a whole is still used in its intended way during the study, i.e. to "restore a level of auditory sensation". All basic safety features incorporated in the implant system remain active and are not affected by the study. The Naída CROS device also works in its intended way without the need for programming. However, the investigational Naída CROS device will be pre-configured with a research software to instantaneously communicate with the approved Naída CI processor when switched on.
Study design
- Primary purpose
- Device feasibility
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| 11 unilateral adult cochlear implant users | Other | Device: Naída CROSSpeech Reception Threshold (SRT) measured with an adaptive test |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Age of 18 years or older
- Unilaterally implanted with an Advanced Bionics Clarion or HiRes90k (implant type) implant
- At least 6 months of cochlear implant use
- At least 3 months experience with the Naída CI processor
- No benefit or limited benefit with a contralateral hearing aid
Key exclusion criteria (3 listed)
- Persons mentioned in the following articles of the French public health code: articles from L. 1121-5 to L.1121-8
- Participating in another clinical study
- Difficulties additional to hearing impairment that would interfere with the study procedures
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Naída CROSAt fitting Naída CROS and a loaner Naída CI processor are used for the duration of the study. The fitting software allows to enable a HIBAN link between the CI processor and the Naída CROS. The fitting of the CI processor is based on the clinical programming of the subject. No changes are made to the fitting parameters unless the subject requests changes. The fitting is done according to the clinical routine. The Naída CROS is pre-configured to communicate with the Naída CI when switched on. | Device | 11 unilateral adult cochlear implant users |
Primary outcome
Speech Reception Threshold (SRT) measured with an adaptive test (French Matrix sentence test)
Time frame: Baseline
Speech tests in quiet \& noise with the Naída CI processor alone and with the Naída CROS device
Speech Reception Threshold (SRT) measured with an adaptive test (French Matrix sentence test)
Time frame: 1 month
Speech tests in quiet \& noise with the Naída CI processor alone and with the Naída CROS device
Speech Reception Threshold (SRT) measured with an adaptive test (French Matrix sentence test)
Time frame: 3 months
Speech tests in quiet \& noise with the Naída CI processor alone and with the Naída CROS device
Speech Reception Threshold (SRT) measured with an adaptive test (French Matrix sentence test)
Time frame: Baseline
Questionnaires about Naída CI sound processor and Naída CROS device listening condition
Speech Reception Threshold (SRT) measured with an adaptive test (French Matrix sentence test)
Time frame: 1 month
Questionnaires about Naída CI sound processor and Naída CROS device listening condition
Speech Reception Threshold (SRT) measured with an adaptive test (French Matrix sentence test)
Time frame: 3 months
Questionnaires about Naída CI sound processor and Naída CROS device listening condition
8 secondary outcomes
Questionnaires about Naída CI sound processor listening condition
Time frame: Baseline
Questionnaires about Naída CI sound processor listening condition
Time frame: Baseline
Questionnaires about Naída CI sound processor listening condition
Time frame: 1 months
Questionnaires about Naída CI sound processor listening condition
Time frame: 1 months
Questionnaires about Naída CI sound processor listening condition
Time frame: 3 months
Questionnaires about Naída CI sound processor listening condition
Time frame: 3 months
Questionnaires about Naída CI sound processor listening condition
Time frame: 3.5 months
Questionnaires about Naída CI sound processor listening condition
Time frame: 3.5 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Aug 2017.
- Individual participant dataSharing planned: No
Related trials for Cochlear Implants
RecruitingObservational study
Retrospective Analysis of Speech Performance Using the HiRes Ultra and HiRes Ultra 3D Cochlear Implant
Cochlear Hearing Loss
RecruitingObservational study
Retrospectively Investigating Longitudinal Outcomes in MED-EL SONATA 2 Cochlear Implant Recipients.
Cochlear Implantation, Sensorineural Hearing Loss
Recruiting
Cochlear Implants and Listening Effort: the Interaction of Cognitive and Sensory Constraints
Cochlear Implant Users
Recruiting
Investigating Auditory Processing in the Users of Auditory Brainstem and Cochlear Implants
Deafness
Not yet recruitingObservational study
Mi2000 TICI Follow-up
Hearing Loss, Binaural, Cochlear Implantation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Volkmar Hamacher, Dr. study chair
Advanced Bionics GmbH
Isabelle MOSNIER, Dr. principal investigator
Groupe Hospitalier de la PITIE-SALPETRIERE
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Naída CROS in people with Cochlear Implants, run by Advanced Bionics AG at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Aug 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Speech Reception Threshold (SRT) measured with an adaptive test (French Matrix sentence test) (time frame: Baseline). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Aug 2017.